DESTINY-Breast Trial Portfolio Spotlights Efficacy of T-DXd in Metastatic Breast Cancer Read More » June 28, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer Read More » June 14, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth Read More » May 23, 2024
Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2– Breast Cancer Read More » May 21, 2024
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer Read More » April 15, 2024
